Brief: New Data Suggest Veracyte’S Envisia Genomic Classifier Can Help Predict Disease Progression In Interstitial Lung Disease Patients Treated With Combination Immunosuppressive Therapy
07/09/2022 22:13
Sept 7 (Reuters) - Veracyte Inc VCYT.O :
* NEW DATA SUGGEST VERACYTE’S ENVISIA GENOMIC CLASSIFIER CAN
HELP
PREDICT DISEASE PROGRESSION IN INTERSTITIAL LUNG DISEASE
PATIENTS TREATED WITH COMBINATION IMMUNOSUPPRESSIVE THERAPY
Source text for Eikon: ID:nBwK4dvsa
Further company coverage: VCYT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Veracyte
See all newsU.S. STOCKS ON THE MOVE-Vor Biopharma, Fair Isaac Corp, Plug Power
U.S. STOCKS ON THE MOVE-Snowflake, Cboe, Oracle
US STOCKS ON THE MOVE-Veracyte, Staar Surgical, Corning
Veracyte gains on data supporting use of prostate cancer test to guide treatment decisions
Corrected: U.S. RESEARCH ROUNDUP-Abbvie, Amazon, Illumina